2007
DOI: 10.1016/j.brachy.2007.01.006
|View full text |Cite
|
Sign up to set email alerts
|

Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
25
0
1

Year Published

2008
2008
2016
2016

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 22 publications
(26 citation statements)
references
References 37 publications
0
25
0
1
Order By: Relevance
“…Presenting baseline rectal, urinary, and erectile functions were prospectively assessed at the time of initial clinical evaluation, in the majority of the cohort, to monitor for potential acute and chronic treatment-related toxicity. As previously described in detail, our SPECT/CT BTV IGRT-DE protocol demonstrated limited and acceptable toxicity for the cohort (11)(12)(13).…”
Section: Methodsmentioning
confidence: 90%
See 3 more Smart Citations
“…Presenting baseline rectal, urinary, and erectile functions were prospectively assessed at the time of initial clinical evaluation, in the majority of the cohort, to monitor for potential acute and chronic treatment-related toxicity. As previously described in detail, our SPECT/CT BTV IGRT-DE protocol demonstrated limited and acceptable toxicity for the cohort (11)(12)(13).…”
Section: Methodsmentioning
confidence: 90%
“…Neither conventional CaP imaging nor any other staging method, including PLND studies in 65 patients (27.2%), could confirm the presence of distant metastatic uptake suggested by SPECT/CT (mets). Therefore, these findings were assumed to represent probable false positive results; and all subjects were followed without alteration in disease management; as previously described in detail (10)(11)(12)(13).…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…(Adapted and reproduced permission of reference [115].) Anatomic localization, evaluation of therapeutic efficacy for pancreatic chemotherapy [180,[191][192][193] Parathyroid gland 99m Tc-sestamibi Anatomical localization [161,[194][195][196][197][198] Pheochromocytoma 123 I-metaiodobenzylguanidine Anatomical localization [189] Prostate cancer 111 In-capromab pendetide Attenuation correction, anatomical localization, monitoring brachytherapy [12,26,[199][200][201][202][203][204] Whole body (phantom study) Technetium-99m Attenuation correction, radioimmunotherapy dosimetry [226] …”
Section: Discussionmentioning
confidence: 99%